The IRCM, a well-established centre of excellence in RNA research in Quebec, welcomes Moderna's decision to establish its new RNA-based vaccine plant in Montreal.
‘’The establishment of a center of expertise and an RNA-based vaccine production plant in Quebec opens the door to the development of Canada's autonomy in vaccine production and to innovative collaborations between experts in the field, including those at IRCM," said Jean-François Côté, Scientific Director and Interim President of IRCM.
The potential of RNAs, molecules made up of ribonucleotides with multiple functions in the cell, is currently being explored in laboratories around the world, including those of several IRCM research teams. Its therapeutic potential is vast, affecting several major pathologies.
A Montreal event on the theme of RNA
Note that the IRCM will offer, as part of the 3rd edition of EFFERVESCENCE - The Future of Life Sciences! (Montréal InVivo), on May 11, a session dedicated to therapeutic RNA, its potential, its applications and its current and future applications, with several prominent panelists, including IRCM researchers.
Contact:
Florence Meney
Directrice des communications, IRCM
florence.meney@ircm.qc.ca
514 755-2516
